RALEIGH, NC, July 26, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, has been recognized as the World's Premier Research Consulting Organization (RCO) by PharmaTech Outlook in their esteemed 'Top 20 CROs' edition.
The 'Top 20 CROs' edition of PharmaTech Outlook is a highly anticipated annual list that highlights trailblazers in the industry. The selection process is meticulous and involves extensive industry research, interviews, and client reviews/testimonials to identify companies at the forefront of driving positive and disruptive change within the industry. Inclusion on this list and acknowledgement by PharmaTech Outlook as the World's Premier Research Consulting Organization is not just an honor, but a testament to the years of innovation, dedication, expertise, and collaboration that have been the cornerstone of ProPharma's overarching growth strategy and transformation journey.
Bryan Katz, ProPharma's Chief Strategy Officer / Head of Corporate Development, said: "We are honored to be named as the World's Premier Research Consulting Organization by PharmaTech Outlook. This recognition underscores our relentless commitment to advancing science through innovative services and solutions and is a testament to the tireless efforts of our exceptional teams who consistently go above and beyond."
This accolade highlights ProPharma's ongoing commitment to revolutionize the industry by offering a fully customizable suite of services and solutions, underpinned by a team of industry-leading subject matter experts.
With an unwavering focus on quality, innovation, and client satisfaction, ProPharma's recognition by PharmaTech Outlook underscores its fervent drive to excel, innovate, and carve new paths in research consulting to benefit global health. With a future-forward view, ProPharma remains committed to delivering scientific rigor and operational excellence to deliver its purpose to improve the health and safety of patients worldwide.
###
Media Inquiries and Contacts:
Zosya Popik Vice President, Global Marketing
ProPharma
zosya.popik@propharmagroup.com
Steve Rensi Senior Director, Global Brand Strategy & Communications
ProPharma
steve.rensi@propharmagroup.com
Jason Wakeford Senior Vice President, Communications
Clarity for ProPharma
propharma@clarity.global
